JP2021151253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021151253A5 JP2021151253A5 JP2021099897A JP2021099897A JP2021151253A5 JP 2021151253 A5 JP2021151253 A5 JP 2021151253A5 JP 2021099897 A JP2021099897 A JP 2021099897A JP 2021099897 A JP2021099897 A JP 2021099897A JP 2021151253 A5 JP2021151253 A5 JP 2021151253A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- mammalian cell
- set forth
- sequence set
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004962 mammalian cell Anatomy 0.000 claims 20
- 102000040430 polynucleotide Human genes 0.000 claims 16
- 108091033319 polynucleotide Proteins 0.000 claims 16
- 239000002157 polynucleotide Substances 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 6
- 241000699800 Cricetinae Species 0.000 claims 3
- 230000001605 fetal effect Effects 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023018535A JP7532571B2 (ja) | 2017-04-20 | 2023-02-09 | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487550P | 2017-04-20 | 2017-04-20 | |
| US62/487,550 | 2017-04-20 | ||
| JP2019551563A JP6900500B2 (ja) | 2017-04-20 | 2018-04-16 | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551563A Division JP6900500B2 (ja) | 2017-04-20 | 2018-04-16 | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023018535A Division JP7532571B2 (ja) | 2017-04-20 | 2023-02-09 | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021151253A JP2021151253A (ja) | 2021-09-30 |
| JP2021151253A5 true JP2021151253A5 (enExample) | 2021-12-09 |
| JP7227312B2 JP7227312B2 (ja) | 2023-02-21 |
Family
ID=62111232
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551563A Active JP6900500B2 (ja) | 2017-04-20 | 2018-04-16 | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 |
| JP2021099897A Active JP7227312B2 (ja) | 2017-04-20 | 2021-06-16 | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 |
| JP2023018535A Active JP7532571B2 (ja) | 2017-04-20 | 2023-02-09 | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551563A Active JP6900500B2 (ja) | 2017-04-20 | 2018-04-16 | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023018535A Active JP7532571B2 (ja) | 2017-04-20 | 2023-02-09 | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10647759B2 (enExample) |
| EP (1) | EP3612559A1 (enExample) |
| JP (3) | JP6900500B2 (enExample) |
| KR (2) | KR102567295B1 (enExample) |
| CN (2) | CN110582511B (enExample) |
| AR (1) | AR111208A1 (enExample) |
| AU (2) | AU2018255221B2 (enExample) |
| BR (1) | BR112019018810A2 (enExample) |
| CA (1) | CA3058482C (enExample) |
| CL (1) | CL2019002922A1 (enExample) |
| CO (1) | CO2019011349A2 (enExample) |
| CR (1) | CR20190445A (enExample) |
| DO (1) | DOP2019000241A (enExample) |
| EA (1) | EA201992163A1 (enExample) |
| EC (1) | ECSP19075146A (enExample) |
| IL (1) | IL269003B2 (enExample) |
| JO (1) | JOP20190247A1 (enExample) |
| MA (1) | MA50144A (enExample) |
| MX (2) | MX2019012445A (enExample) |
| NZ (1) | NZ758066A (enExample) |
| PE (1) | PE20200011A1 (enExample) |
| PH (1) | PH12019502361A1 (enExample) |
| SA (1) | SA519410311B1 (enExample) |
| SG (1) | SG11201909022PA (enExample) |
| TW (2) | TWI705975B (enExample) |
| UA (1) | UA126806C2 (enExample) |
| WO (1) | WO2018194951A1 (enExample) |
| ZA (1) | ZA202007868B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| WO2020193644A1 (en) | 2019-03-26 | 2020-10-01 | Janssen Pharmaceutica Nv | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF |
| WO2021151011A2 (en) * | 2020-01-24 | 2021-07-29 | The Board Of Trustees Of Western Michigan University | Treatment of neurodegenerative proteinopathies using fas apoptosis inhibitory molecule (faim) or a fragment and/or a mimetic thereof |
| AU2021355518A1 (en) * | 2020-10-02 | 2023-06-08 | Eli Lilly And Company | Methods for reducing host cell protein content in protein purification processes |
| TWI843040B (zh) | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| TW202300518A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| JP7306745B2 (ja) * | 2021-09-16 | 2023-07-11 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
| JP7306746B2 (ja) * | 2021-09-16 | 2023-07-11 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
| JP7268910B2 (ja) * | 2021-09-16 | 2023-05-08 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
| CA3235104A1 (en) * | 2021-10-22 | 2023-04-27 | Kevin BIGLAN | O-glcnacase (oga) inhibitor combination therapy |
| CN118475609A (zh) | 2021-10-29 | 2024-08-09 | 伊莱利利公司 | 靶向白细胞介素-34的化合物和方法 |
| TW202336034A (zh) | 2021-10-29 | 2023-09-16 | 美商美國禮來大藥廠 | 靶向介白素-34之化合物及方法 |
| KR20240105403A (ko) | 2021-10-29 | 2024-07-05 | 일라이 릴리 앤드 캄파니 | 인터류킨-34를 표적화하는 화합물 및 방법 |
| KR20240099347A (ko) | 2021-10-29 | 2024-06-28 | 일라이 릴리 앤드 캄파니 | 인터류킨-34를 표적화하는 화합물 및 방법 |
| EP4472679A1 (en) | 2022-02-03 | 2024-12-11 | Eli Lilly and Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
| CN117327168A (zh) * | 2022-06-24 | 2024-01-02 | 厦门大学 | B2M-GluN1封闭肽、其药物组合物及用途 |
| AU2023382603A1 (en) * | 2022-11-17 | 2025-07-03 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA ANTIBODIES, DOSES, AND USES THEREOF |
| EP4638494A1 (en) | 2022-12-22 | 2025-10-29 | BioArctic AB | Antibody which binds to abetape3 |
| WO2025106313A1 (en) | 2023-11-14 | 2025-05-22 | Eli Lilly And Company | Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES |
| CN118459583B (zh) * | 2024-07-11 | 2024-09-10 | 齐鲁制药有限公司 | 抗N3pGlu淀粉样蛋白β抗体及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100767146B1 (ko) * | 2000-02-24 | 2007-10-15 | 워싱톤 유니버시티 | Ａβ 펩티드를 격리시키는 인간화 항체 |
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| CA2487528A1 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| UY29504A1 (es) * | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| TWI551607B (zh) | 2006-07-14 | 2016-10-01 | Ａｃ免疫公司 | 人類化抗體 |
| WO2009149487A2 (en) | 2008-06-12 | 2009-12-17 | Affiris Ag | Compounds for treating symptoms associated with parkinson's disease |
| JP2011527338A (ja) | 2008-07-09 | 2011-10-27 | ユニバーシティー オブ チューリッヒ | 神経新生を促進する方法 |
| JP5828762B2 (ja) | 2008-07-21 | 2015-12-09 | プロビオドルグ エージー | 診断用抗体アッセイ |
| EP2576617B1 (en) | 2010-06-04 | 2016-04-27 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS |
| LT3042917T (lt) * | 2010-08-12 | 2018-05-10 | Eli Lilly And Company | Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas |
| WO2012021475A2 (en) | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| WO2015175769A1 (en) * | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| TWI599358B (zh) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| ES3012402T3 (en) * | 2015-04-13 | 2025-04-09 | Pfizer | Therapeutic antibodies and their uses |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
-
2017
- 2017-06-16 JO JOP/2019/0247A patent/JOP20190247A1/ar unknown
-
2018
- 2018-04-09 TW TW107112023A patent/TWI705975B/zh active
- 2018-04-09 TW TW109140166A patent/TWI789644B/zh active
- 2018-04-09 AR ARP180100882A patent/AR111208A1/es unknown
- 2018-04-16 EA EA201992163A patent/EA201992163A1/ru unknown
- 2018-04-16 UA UAA201910202A patent/UA126806C2/uk unknown
- 2018-04-16 JP JP2019551563A patent/JP6900500B2/ja active Active
- 2018-04-16 SG SG11201909022P patent/SG11201909022PA/en unknown
- 2018-04-16 PE PE2019002050A patent/PE20200011A1/es unknown
- 2018-04-16 EP EP18722325.0A patent/EP3612559A1/en active Pending
- 2018-04-16 BR BR112019018810A patent/BR112019018810A2/pt unknown
- 2018-04-16 IL IL269003A patent/IL269003B2/en unknown
- 2018-04-16 KR KR1020227001314A patent/KR102567295B1/ko active Active
- 2018-04-16 CN CN201880025982.6A patent/CN110582511B/zh active Active
- 2018-04-16 WO PCT/US2018/027718 patent/WO2018194951A1/en not_active Ceased
- 2018-04-16 KR KR1020197030416A patent/KR102352670B1/ko active Active
- 2018-04-16 CR CR20190445A patent/CR20190445A/es unknown
- 2018-04-16 NZ NZ758066A patent/NZ758066A/en unknown
- 2018-04-16 CN CN202310757235.4A patent/CN117024583A/zh active Pending
- 2018-04-16 AU AU2018255221A patent/AU2018255221B2/en active Active
- 2018-04-16 MA MA050144A patent/MA50144A/fr unknown
- 2018-04-16 US US15/953,716 patent/US10647759B2/en active Active
- 2018-04-16 CA CA3058482A patent/CA3058482C/en active Active
- 2018-04-16 MX MX2019012445A patent/MX2019012445A/es unknown
-
2019
- 2019-09-20 DO DO2019000241A patent/DOP2019000241A/es unknown
- 2019-10-14 CL CL2019002922A patent/CL2019002922A1/es unknown
- 2019-10-15 CO CO2019011349A patent/CO2019011349A2/es unknown
- 2019-10-16 SA SA519410311A patent/SA519410311B1/ar unknown
- 2019-10-17 MX MX2022011817A patent/MX2022011817A/es unknown
- 2019-10-17 PH PH12019502361A patent/PH12019502361A1/en unknown
- 2019-10-18 EC ECSENADI201975146A patent/ECSP19075146A/es unknown
-
2020
- 2020-04-08 US US16/843,503 patent/US11078261B2/en active Active
- 2020-12-17 ZA ZA2020/07868A patent/ZA202007868B/en unknown
-
2021
- 2021-06-14 AU AU2021203927A patent/AU2021203927B2/en active Active
- 2021-06-16 JP JP2021099897A patent/JP7227312B2/ja active Active
- 2021-08-02 US US17/391,821 patent/US20210371509A1/en not_active Abandoned
-
2023
- 2023-02-09 JP JP2023018535A patent/JP7532571B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021151253A5 (enExample) | ||
| JP2021019642A5 (enExample) | ||
| AR120511A2 (es) | Producción de proteínas heteromultiméricas | |
| JP2020018311A5 (enExample) | ||
| JP2022169664A5 (enExample) | ||
| RU2020131199A (ru) | Способ тестирования производственного процесса получения рекомбинантного белка | |
| RU2012150346A (ru) | Улучшенная среда для культивирования клеток | |
| HRP20211882T1 (hr) | Protutijela protiv cd40 i njihova upotreba | |
| JP2016105737A5 (enExample) | ||
| JP2014524241A5 (enExample) | ||
| RU2013111533A (ru) | Способы получения мультиспецифичных и мультивалентных антител | |
| ATE481483T1 (de) | Verfahren zur herstellung eines rekombinanten polyklonalen proteins | |
| JP2011525355A5 (enExample) | ||
| RU2010108308A (ru) | Способ получения гетерогенных белков | |
| JP2008500050A5 (enExample) | ||
| JP2015514423A5 (enExample) | ||
| JPWO2020072821A5 (enExample) | ||
| RU2015144172A (ru) | Композиции клеточных культур с антиоксидантами и способы получения полипептидов | |
| RU2015148746A (ru) | Новый способ клонирования, экспрессии и очистки для получения ранибизумаба | |
| JP2012516686A5 (enExample) | ||
| DE502006002453D1 (de) | Verfahren für die kontinuierliche zielgerichtete evolution von proteinen in vitro | |
| JP2020509763A5 (enExample) | ||
| JP2020527727A5 (enExample) | ||
| IL307155B1 (en) | Antibodies with modulated glycan profiles | |
| JP2011505811A5 (enExample) |